title: BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate?
authors: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA (DD, JMK); Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA (SYF).
authors: Diwakar
authors: D
authors: Davar
authors: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA (DD, JMK); Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA (SYF).
authors: Serge Y
authors: SY
authors: Fuchs
authors: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA (DD, JMK); Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA (SYF). kirkwoodjm@upmc.edu.
authors: John M
authors: JM
authors: Kirkwood
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy*; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D053633:Receptor, Interferon alpha-beta / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D016898:Interferon-alpha; D053633:Receptor, Interferon alpha-beta; D048493:Proto-Oncogene Proteins B-raf